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CCR5Human immunodeﬁciency virus type 1 (HIV-1) originated in chimpanzees; yet, several previous studies
have shown that primary HIV-1 isolates replicate poorly in chimpanzee CD4+ T lymphocytes in vitro and in
vivo. The reasons for this apparent restriction are not understood. Here, we describe a new activation
protocol that led to a reproducible expansion and activation of chimpanzee CD4+ T lymphocytes in vitro.
Using this protocol, we uncovered species-speciﬁc differences in the activation proﬁles of human and
chimpanzee CD4+ T-cells, including HLA-DR and CD62L. Moreover, we found that improved activation
facilitated the replication of both CXCR4 and CCR5-tropic HIV-1 in CD4+ T-cell cultures from over 30
different chimpanzees. Thus, the previously reported “replication block” of CCR5-tropic HIV-1 in chimpanzee
lymphocytes appears to be due, at least in large part, to suboptimal T-cell activation.
© 2009 Elsevier Inc. All rights reserved.Introduction
Chimpanzees are 98% genetically identical to humans and were
one of the ﬁrst non-human primate species that were experimentally
infected with HIV-1 in an attempt to develop an animal model for
AIDS pathogenesis (Alter et al., 1984; Gendelman et al., 1991;
Watanabe et al., 1991). Early studies showed that certain strains of
HIV-1 were capable of establishing a persistent infection in chimpan-
zees in vivo; however, all of these were T-cell-line-adapted viruses. In
contrast, primary HIV-1 isolates generally failed to replicate in
chimpanzee CD4+ T lymphocytes, and this was true in vitro as well
as in vivo (Benton et al., 1999; Bogers et al., 1998; Gendelman et al.,
1991; Pischinger et al., 1998; Schuitemaker et al., 1993; Shibata et al.,
1995; Watanabe et al., 1991). In fact, it was subsequently determined
that all HIV-1 strains capable of replicating in chimpanzee PBMCs in
vitro used the CXCR4 chemokine receptor for entry, either exclusively
(X4) or as dual tropic (X4R5) strains (Cho et al., 1996; Schuitemaker
et al., 1993; Shibata et al., 1995). Conversely, HIV-1 primary isolates
that were CCR5 tropic (R5) failed to establish a productive infection in
chimpanzee PBMCs in vitro (Benton et al., 1999; Cho et al., 1996;
Ondoa et al., 2002; Schuitemaker et al., 1993; Shibata et al., 1995)..
ll rights reserved.Collectively, these ﬁndings were taken to indicate that there was a
coreceptor-dependent entry restriction for HIV-1 in chimpanzee cells.
The apparent replication block of R5 strains was difﬁcult to
reconcile with the subsequent observation that naturally occurring
SIVcpz strains were all R5 tropic (Bibollet-Ruche et al., 2004; Muller-
Trutwin et al., 2000; Ondoa et al., 2001; Takehisa et al., 2007).
Moreover, R5 HIV-1 variants were subsequently identiﬁed, which
were capable of establishing a persistent infection in vivo (Conley et
al., 1996; ten Haaft et al., 2001). Finally, human and chimpanzee CCR5
differ by only two amino acids, at position 13 (Asn in human, Asp in
chimpanzee) and position 130 (Val in human, Ile in chimpanzee), and
multiple studies have shown that these two positions are not involved
in HIV-1 gp120 binding (Benton, Lee, and Kennedy, 1998; Dragic et al.,
1998; Martin et al., 1997; Muller-Trutwin et al., 1999; Pretet et al.,
1997; Samson et al., 1996; Zacharova, Zachar, and Goustin, 1997).
Survey of a large number of chimpanzees also failed to identify
inactivating mutations of the CCR5 gene, such as the CCR5-Δ32
nonfunctional human allele (Martinson et al., 1997; Mummidi et al.,
2000; ten Haaft et al., 1997; Voevodin, Samilchuk, and Dashti, 1998).
Together, these ﬁnding argued against a coreceptor-related entry
block of R5 tropic HIV-1 in chimpanzees T lymphocytes.
The lack of replication of HIV-1 R5 isolates in chimpanzee T-cells
could be explained by a differential CCR5 expression on in vitro-
activated chimpanzee compared to human lymphocytes. A minimal
CCR5 threshold appears to be required for efﬁcient viral entry and this
Fig. 1. HIV-1 SG3 replication in PHA-activated chimpanzee and human CD4+
lymphocytes. (A) CD4+ lymphocytes from eight chimpanzees (C1 to C8) and six
human (H1 to H6) donors were activated with PHA and tested for their ability to
support HIV-1 SG3 replication. Infections were initiated at a multiplicity of infection
(MOI) of 0.1. Virus replication was monitored by quantifying the p24 viral antigen in
the culture supernatants on day 8 post-infection (y-axis, nanograms of p24 per ml of
culture supernatant). The grey box indicates the cutoff (1 ng/ml) below which
replication is considered negative. (B) Representative ﬂow cytometric density plots (x-
axis, electronic volume; y-axis, side scatter) of CD4+ lymphocytes at baseline (left
panels) and 48 h post PHA activation (right panels) for human (top panels) and
chimpanzee (lower panels). The percentage of activated cells located in gate R2 are
indicated.
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Simmons, and Clapham, 1999; Lin et al., 2002; Platt et al., 1998). CCR5
cell surface expression on activated human CD4+ lymphocytes varies
considerably among different human donors, possibly because of
polymorphisms in the CCR5 5′ cis-regulatory region (Lee et al., 1999;
Trkola et al., 1996; Wu et al., 1997). Polymorphisms in the
chimpanzee CCR5 5′ cis-regulatory region have been reported,
distinct from the polymorphisms found in humans (Bamshad et al.,
2002; Tang et al., 1999; Wooding et al., 2005). CCR5 expression on
human CD4+ T lymphocytes is known to be dependent on the degree
of cellular activation, on memory versus naïve phenotypes of these
cells and on the ligand used for polyclonal T-cell activation (Bleul et
al., 1997; Mengozzi et al., 2001; Riley et al., 1998). Indeed
phytohemagglutinin (PHA), the mitogen used in most previous
studies of chimpanzee PBMCs activation, is rather ineffective at
inducing CCR5 cell surface expression in human CD4+ lymphocytes
(Bleul et al., 1997). The secretion of β-chemokines, such as CCL3 (MIP-
1 alpha), CCL4 (MIP-1 beta) or CCL5 (RANTES), by chimpanzee T-cells
could also account for the replication block of HIV-1 R5 strains in vitro.
These β-chemokines can block infection either directly via blocking
gp120-CD4 interaction or indirectly by inducing CCR5 internalization
(Creson et al., 1999; Mack et al., 1998; Riley et al., 1997; Sabbe et al.,
2001). Consistent with this hypothesis, the gene copy number of the
β-chemokine CCL3L1, a duplicated isoform of CCL3, was reported to
be higher in chimpanzees compared to humans (Gonzalez et al., 2005;
Shao et al., 2007).
In this study, we asked whether the previously reported failure of
R5 HIV-1 to replicate in chimpanzee CD4+ T-cell cultures might
reﬂect an experimental artifact. Speciﬁcally, we asked whether
different levels of T-cell activation could account for the observed
replication differences, as the level of T-cell activation determines the
level of HIV-1 replication. Our results show that this is indeed the case.
Employing a novel lymphocyte activation protocol, we show that
chimpanzee CD4+ T-cells can support efﬁcient replication of
prototypic R5 HIV-1 strains.
Results
Limited proliferation of chimpanzee CD4+ T lymphocytes under
standard activation conditions
Standard lymphocyte activation protocols make use of a variety of
agents such as lectins, enterotoxins or monoclonal antibodies that
induce T-cell activation and proliferation via T-cell receptor cross-
linking (Kruisbeek et al., 2004; Vicenzi and Poli, 2005). In an initial set
of experiments, we thus used phytohemagglutinin (PHA) to activate
chimpanzee CD4+ T lymphocytes as previously described (Beaumont
et al., 2000; Gendelman et al., 1991; Nguyen et al., 2006; Schuite-
maker et al., 1993; Shibata et al., 1995; Watanabe et al., 1991).
Replication of the X4-tropic HIV-1 SG3 strain in these PHA-activated
T-cell cultures was highly variable among chimpanzee donors (n=8,
day 8 post-infection median p24=13 ng/ml, range=0–72 ng/ml),
ranging from no replication (n=2) to levels 10-fold lower compared
to human donors (n=6, day 8 post-infection median p24= 193 ng/
ml, range=120–430 ng/ml; Fig. 1A). Although HIV-1 SG3 was
speciﬁcally selected for its ability to efﬁciently replicate in chimpan-
zee T-cells (Ghosh et al., 1993), lymphocytes from some chimpanzee
donors were unable to support SG3 replication under these condi-
tions. Moreover, the R5 strain YU2 did not replicate in any of the
chimpanzee T-cell cultures following this standard protocol (data not
shown). Similar results were obtained when chimpanzee CD4+
lymphocytes were stimulated with concanavalin A (data not shown).
Flow cytometry analysis of PHA-stimulated cells identiﬁed activated
CD4+ lymphocytes in both human and chimpanzee cultures, as
shown by the appearance of larger cells with increased granularity
(Fig. 1B). However, trypan blue staining revealed two- to threefoldlower numbers of viable cells in PHA-activated chimpanzee compared
to human cultures. We thus explored conditions under which human
and chimpanzee CD4+ lymphocytes would be activated and
proliferate to the same extent and supporting HIV-1 replication.
We ﬁrst evaluated a stimulation protocol using anti-CD3 or a
combination of anti-CD3+anti-CD28 monoclonal antibodies (mAbs),
and the results were recently reported (Bibollet-Ruche et al., 2008).
We found that not all anti-CD3 mAb isotype were equally capable of
stimulating chimpanzee T-cells. While immunological activation of
chimpanzee lymphocytes was achieved with anti-CD3 mAbs of the
IgG2a isotype, these activated cells still remained resistant to infection
with the R5 tropic HIV-1 YU2 strain and less supportive of the X4-
tropic HIV-1 SG3 replication compared to human lymphocytes
activated under the same protocol.
We next tested the Staphylococcal enterotoxin B (SEB) super-
antigen activation competence of human and chimpanzee CD4+
lymphocytes. Previous studies demonstrated that bacterial super-
antigens such as SEB induce a more robust proliferative response in
non-human primate T-cells, including macaque and chimpanzee,
compared to lectin stimulation (Bavari et al., 1995; Kakimoto et al.,
1999; Loffredo et al., 2004). As with PHA, we found that cellular
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lymphocyte cultures. However, SEB stimulation increased HIV-1 SG3
replication in both chimpanzee and human CD4+ lymphocytes by 3-
to 40-fold compared to PHA-activated cells (Fig. 2A). Although SEB-
stimulated chimpanzee CD4+ lymphocytes were still refractory to
HIV-1 YU2, a fourfold growth increase was observed in SEB-activated
human cells (Fig. 2B). We thus selected SEB as the mitogen for all
further studies.
Optimization of the activation protocol for chimpanzee CD4+
T lymphocytes
Original experiments aimed at deciphering the mode of action of
mitogens, such as PHA or SEB, in respect to T-cell activation were
performed in the presence of antigen presenting cells (APCs),
including dendritic cells and macrophages (Bhardwaj et al., 1993;
Boshell et al., 1996; Damaj et al., 1992; Hewitt et al., 1992; Mills et al.,
1985; Spertini et al., 1991; Wakasugi et al., 1985). We thus
hypothesized that APCs, speciﬁcally macrophages, may provide
additional signals, via direct cell–cell contact or cytokine production
that could promote and sustain activation of chimpanzee T lympho-
cytes. To induce monocyte differentiation into macrophages, we
supplemented the culture medium with 10% giant cell tumorFig. 2. HIV-1 replication in PHA- or SEB-activated T-cells. CD4+ lymphocytes from
three chimpanzees (C-1 to C-3) and one human (H-1) donors were activated with PHA
or SEB and tested for their ability to support HIV-1 SG3 (A) and YU2 (B) replication.
Infections were initiated at a multiplicity of infection (MOI) of 0.1. Virus replication was
monitored by quantifying the p24 viral antigen in the culture supernatants on day
8 post-infection (y-axis, nanograms of p24 per ml of culture supernatant). Virus
replication was considered positive when the p24 antigen level reaches a cutoff value of
1 ng /ml (shaded box). For the three chimpanzee cultures, the median p24 level for the
SG3 infections the in PHA-activated cells was 5.8 ng/ml and the median p24 in SEB-
activated cells was 88.3 ng/ml.conditioned medium, which contains M-CSF. Similar activation
schemes using SEB-pulsed dendritic cells for the expansion of
human CD4+ lymphocytes have recently been described (Oswald-
Richter et al., 2007; Unutmaz et al., 1999). The results showed that
chimpanzee, as well as human, CD4+ lymphocytes activated by SEB
and cocultured in the presence of autologous monocyte-derived
macrophages exhibit a strong and reproducible proliferative response.
Phenotypic characterization of activated lymphocytes
Differences in susceptibility to HIV-1 infection have been reported
for various human lymphocyte populations, including naïve and
memory T-cells, subsets of memory cells, as well as cells with T helper
type 1 (Th1) or type 2 (Th2) phenotypes (Annunziato et al., 2000;
Bonecchi et al., 1998; Cayota et al., 1993; Chun et al., 1997; Oswald-
Richter et al., 2007; Song et al., 2005b). We thus determined the
phenotype of the activated lymphocytes to ensure that HIV-1
replication in human and chimpanzee cultures was not biased by
species-speciﬁc differences in the expanded T-cell populations.
For 16 chimpanzee and 7 human donors, activated CD4+ T-cells
were analyzed for the expression of lymphocyte surface markers.
Flow cytometric analyses were performed using monoclonal anti-
bodies against human cell surface antigens known to cross-react with
the cognate chimpanzee antigen. The expanded cells were CD3+
CD4+ with a reproducible purity of over 90% (data not shown). The
cell surface markers expression proﬁles for representative human and
chimpanzee are shown in Fig. 3. The magnitude of expression for CD4,
CD69, CD25, CCR5, CD28 and CD45RO was comparable between
chimpanzees and humans (Fig. 4). The mean ﬂuorescence intensity of
these markers on activated lymphocytes was not statistically
signiﬁcant between human and chimpanzees (pN0.1) and showed
limited inter-individual differences (data not shown). Expression of
the CD69 and CD25 early and late activation markers, respectively,
were comparable between human and chimpanzee. On average, N50%
of the cells expressed CD25, indicative of an activated phenotype
(Fig. 4). The CXCR4, CD62L and CD45RA markers were consistently
detected on chimpanzee T-cells, while their expression was lower or
not detected on human T-cells (Figs. 3 and 4). Signiﬁcantly lower
levels of HLA-DR expressing cells were detected in chimpanzee
compared to human cultures (p=0.0002). Further analysis of HLA-DR
expression prior to activation revealed low expression on CD4+
lymphocytes and high expression on monocytes for both human and
chimpanzee cultures (Fig. 5). Thus, T-cell activation induced HLA-DR
expression in human but not chimpanzee CD4+ lymphocytes (Fig. 5).
The HIV-1 coreceptor CCR5 was expressed at high levels in both
species, while CXCR4 expression was signiﬁcantly lower in humans
(p=0.01; Figs. 3 and 4). Activated lymphocytes also expressed the
CD45RO marker, indicating that the expanded cells were derived from
the memory subset (Figs. 3 and 4). Analysis of the CD45RO and
CD45RA markers expression on CD4+ lymphocytes prior to stimu-
lation revealed that naïve (CD45RA+) and memory (CD45RO+)
subsets were equally represented (data not shown), indicating that
our activation procedure preferentially induced the proliferation of
CD4+ CD45RO+ memory lymphocytes. Low levels of the CD45RA
marker were consistently detected on chimpanzee cells while not
detected on human cells (p=0.0005; Figs. 3 and 4). Cells from human
donors expressed low to undetectable levels of the CD62L marker,
while this marker was expressed at higher levels on chimpanzee T-
cells (p=0.0009; Figs. 3 and 4). Upon stimulation, cell surface CD62L
is hydrolyzed by metalloproteases and the low expression on human
cells is likely due to degradation as no metalloproteinase inhibitors
were included during the activation procedure or during the 24-
h incubation in complete media (Kayagaki et al., 1995; Preece et al.,
1996). The CD62L expression detected on activated chimpanzee
cells suggests a differential regulation of L-selectin between human
and chimpanzees.
Fig. 3. Phenotype of activated human and chimpanzee lymphocytes. Activated CD4+ T-cells were stained and analyzed for cell surface activation (CD69, HLA-DR, CD25) and
phenotypic (CD28, CD45RO, CD62L and CD45RA) markers expression as described in Materials and methods. Expression of the HIV-1 CD4 receptor as well as the CCR5 and CXCR4
coreceptors was also analyzed. Representative histogram proﬁles are shown for one human (left panels) and one chimpanzee (right panels) donor (x-axis: log ﬂuorescence, y-axis:
cell number). The electronic gate was set for the CD4+ lymphocyte population, and the percentage of cells expressing this maker were calculated using the same gate for all stains.
Fig. 4. Surface expression of select antigens on activated CD4+ lymphocytes. Activated
CD4+ lymphocytes from 16 chimpanzee (open circles) and 7 human (ﬁlled squares)
donors were stained with antibodies as described in Materials and methods. Surface
antigen expression is shown as the percentage of cells expressing the indicated antigen
from the CD4+ lymphocytes population electronic gate (y-axis). For each antigen, a red
horizontal bar indicates the median value for human and chimpanzee donors. p values
were obtained fromMann–Whitney tests between human and chimpanzee donors, and
non-signiﬁcant (pN0.01) values were omitted.
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and interleukin-4 (IL-4) by activated lymphocytes as markers for Th1
and Th2 subsets, respectively. No IL-4 production (detection limit 1 pg/
ml) and high level of IFN-γwere detected in both species. The average
level IFN-γ in culture supernatant was 985 pg/ml (range=77–2168,
median=898 pg/ml) and 968 pg/ml (range=176–2877 pg/ml,
median=780 pg/ml) in human- and chimpanzee-activated CD4+
lymphocytes culture supernatants, respectively. The IFN-γ levels were
not statistically different between species. These results indicate that
the lymphocytes expanded under our protocol are predominantly from
the Th1 subset.Beta-chemokines secretion by activated lymphocytes
Although there was no signiﬁcant difference in the number of
CCR5 expressing cells between activated human and chimpanzee
lymphocytes (Fig. 4), a higher production of CCR5-binding chemo-
kines (CCL5, CCL3, CCL4) by chimpanzee cells could theoretically
block infection (Annunziato et al., 2000; Margolis et al., 1998; Trkola
et al., 1998). This possibility was of particular interest since
chimpanzees were reported to have a higher copy number of the
CCL3L1 gene, an isoform of the CCL3 chemokine (Gonzalez et al.,
2005; Shao et al., 2007). To test this hypothesis, we quantiﬁed the
production of CCL5 and CCL3 (+CCL3L1 isoform as the Bio-Plex assay
detects both chemokines) in the culture supernatants of activated
lymphocytes. High levels of CCL5 were measured in both species and,
surprisingly, a median 10-fold lower secretion of CCL3 was found in
chimpanzee compared to human donors (Fig. 6). The CCL3 expression
Fig. 5. Surface expression of HLA-DR on CD4+ lymphocytes and monocytes.
CD4-positively selected cells (lymphocytes and monocytes) and activated CD4+
lymphocytes were stained with anti-HLA-DR-FITC, anti-CD4-PECy5 and anti-CD3-PE
antibodies. A representative proﬁle for one human (left panels) and one chimpanzee
(right panels) donor is shown (x-axis = log FITC ﬂuorescence, y-axis = cell counts).
Electronic gates were set for lymphocyte (CD4+ CD3+ population) or monocyte
(CD4+ CD3−) populations and HLA-DR expression was analyzed. The percentage of
cells expressing HLA-DR are indicated for each cell type.
113J.M. Decker et al. / Virology 394 (2009) 109–118differences were highly signiﬁcant (p=0.0002). These results
indicate that a higher secretion of CCR5-binding cytokines by
chimpanzee cells does not explain the reported replication block
observed for R5 HIV-1 in chimpanzee lymphocytes.
SG3 and YU2 replication in chimpanzee CD4+ T lymphocytes
We next asked whether chimpanzee lymphocytes activated with
the new protocol support HIV-1 replication, using the HIV-1 SG3 and
YU2 prototypic strains. The results showed that both virusesFig. 6. CCL3 and CCL5 secretion by activated CD4+ lymphocytes. The production of the
CCL3 and CCL5 beta-chemokines was quantiﬁed in the culture supernatant of activated
CD4+ lymphocytes from 7 human (ﬁlled squares) and 17 chimpanzee (open circles)
donors (y-axis, picograms of CCL3 or CCL5 per ml of culture supernatant).replicated in T-cells from all chimpanzee donors tested. Mean p24
levels in the supernatants of SG3- and YU2-infected CD4+ lympho-
cytes of 23 chimpanzees at 7 days post-infection was 375 ng/ml
(range=74–2480 ng/ml, median=374 ng/ml) and 33 ng/ml
(range=1–460 ng/ml, median=40 ng/ml), respectively (Fig. 7A).
This proﬁle was similar to the replication levels of these two viruses in
human CD4+ T lymphocytes, although relative growth differences
between SG3 and YU2 were less pronounced in human lymphocytes.
The chimpanzee cultures exhibited a wider range of HIV-1 replication
compared to human (Fig. 7B and 7C), including ﬁve individuals with
reduced YU2 replication (p24 b10 ng/ml; Fig. 7C). This was not due to
suboptimal activation as SG3 replicated efﬁciently in these same
cultures (p24 values for SG3 at day 7 in these ﬁve chimpanzees:Fig. 7.HIV-1 SG3 and YU2 strains replication potential in chimpanzee and human CD4+
lymphocytes. (A) Median p24 values in the culture supernatant of SG3- (black) or
YU2-infected (grey) in activated CD4+ lymphocytes from chimpanzee (n=23) and
human (n=4) donors. The error bars represent one standard deviation. The p24 antigen
was quantiﬁed 7 days post-infection (y-axis, nanograms of p24 per ml of culture
supernatant), initiated at day 0 at 0.1 MOI. The day 7 p.i. p24 values for SG3 (x-axis) and
YU2 (y-axis) plotted for 6 human (B) and 23 chimpanzee donors (C). The ﬁlled circles
represent the ﬁve chimpanzee donors that supported limited HIV-1 YU2 replication
(p24 b10 ng/ml).
114 J.M. Decker et al. / Virology 394 (2009) 109–118average=488 ng/ml, range=320–670 ng/ml, median=550 ng/ml).
These results thus showed that chimpanzee CD4+ T-cell cultures
differed signiﬁcantly more in their ability to replicate HIV-1 than
human cultures, indicating signiﬁcant intrinsic inter-individual
differences among chimpanzee donors in supporting the replication
various HIV-1 strains.
Susceptibility of chimpanzee CD4+ T lymphocytes to primary
HIV-1 isolates
To validate the SG3 and YU2 isolates replication results, we
next analyzed the replication of the HIV-1 R5 prototypic strains
ADA, BaL and JRCSF in activated CD4+ lymphocytes from four
human and chimpanzee donors. All strains replicated efﬁciently and
with comparable replication kinetics in activated human T-cells
(Fig. 8A). Conversely, the BaL isolate replicated efﬁciently in chim-
panzee cells to levels comparable to the SG3 and YU2 prototypic
strains. The ADA strain typically exhibited lower replication levels
and, unexpectedly, the JRCSF strain did not replicate in CD4+
lymphocytes from any of the chimpanzee donor tested (Fig. 8B).Fig. 8. Primary HIV-1 strains YU2, JRCSF, ADA and BaL replication kinetics in human and
chimpanzee CD4+ lymphocytes. Virus replication was monitored by measuring the
level of the p24 antigen in culture supernatants. Replication curves for each strain are
shown as the average of independent experiments in CD4+ T lymphocytes from four
different chimpanzee and human donors; the error bars represent one standard
deviation calculated for each time point. The grey box indicate the cutoff (1 ng/ml)
below which replication is considered negative.Taken together, these results indicate that the previously reported
failure of R5 HIV-1 to replicate in chimpanzee T-cells was due, at
least in part, to inadequate T-cell activation but also suggest that
chimpanzee donors differ in their susceptibility to HIV-1 infection
or that some human-adapted HIV-1 strains can be restricted for
replication in chimpanzee cells.
Discussion
In this study, we investigated the replication potential of R5 and X4
HIV-1 strains in human and chimpanzee lymphocytes. We show that
efﬁcient and reproducible activation of chimpanzee CD4+ lympho-
cytes can be achieved in the presence of SEB and autologous
macrophages, and that this mode of activation renders chimpanzee
T-cells capable of supporting the replication of both prototypic X4 and
R5 tropic HIV-1 strains. Characterization of activated T-cell also
revealed differences in surface marker between human and chim-
panzee, expanding previously reported species-speciﬁc differences of
cell surface protein expression.
In the past, investigators screened chimpanzees by in vitro culture
to ﬁnd those most susceptible to HIV-1 infection (Eichberg et al.,
1987; Nguyen et al., 2006; Pischinger et al., 1998; Schuitemaker et al.,
1993; Shibata et al., 1995); however, the level of T-cell activation in
these experiments was not determined. A more recent study noted
differences in the proliferative response between human and
chimpanzee T-cells (Nguyen et al., 2006). This suggested that
chimpanzee lymphocytes might require different activation stimuli
than human lymphocytes to support HIV-1 replication. We reasoned
that autologous macrophages might provide signals that would
induce a longer lasting and/or more robust activation state. We
found that the presence of differentiated macrophages early in the
activation process was indeed the key since it facilitated sustained
SEB-induced CD4+ lymphocyte proliferation, a function not provided
by monocytes or B-lymphocytes in this system (FB-R, unpublished).
Chimpanzee CD4+ lymphocytes activated under the new protocol
supported efﬁcient replication of the prototypic R5 YU2 strain,
revealing for the ﬁrst time that the previously reported R5 replication
block was likely a tissue culture artifact (Beaumont et al., 2000; Cho et
al., 1996; Schuitemaker et al., 1993; Shibata et al., 1995). We did,
however, ﬁnd that lymphocytes from different chimpanzee donors
varied in their ability to support YU2 replication, more so than
comparable human cultures (Fig. 7B and C). This was not due to
lymphocyte activation levels, coreceptor expression or availability of
target cells and may thus reﬂect as yet unidentiﬁed host factors that
inﬂuence viral replication. The mechanisms underlying these differ-
ences among chimpanzee donors remain to be explored.
The phenotypic characterization of CD4+ lymphocytes activated
under the new protocol also revealed species-speciﬁc differences in
the expression of surface marker possibly linked to the regulation of
T-cell activation. Because human and chimpanzee monocytes express
comparable levels of HLA-DR, the low level of HLA-DR expression on
activated chimpanzee CD4+ lymphocytes (Fig. 4) suggests that these
cells might be less functional as APCs in vivo compared to their human
counterpart. The role of MHC class II expression on CD4+ lympho-
cytes remain unclear, but several reports suggest that the MHC class
II-mediated interaction between T-cells could regulate adaptive
immune responses (Barnaba et al., 1994; Fischer et al., 2007; LaSalle
et al., 1991). In addition, MHC class II proteins differ in their ability to
bind superantigens such as SEB and amino acid differences between
human and chimpanzee MHC class II have been described (de Groot
and Bontrop, 1999; Herman et al., 1990; Herrmann et al., 1989). Thus,
it is possible that differences in HLA-DR cell surface expression and/or
allelic polymorphism (via differences in SEB afﬁnity) account for the
limited proliferative response of chimpanzee CD4+ lymphocytes to
SEB stimulation in the absence of macrophages. Activated chimpanzee
CD4+ lymphocytes also expressed high levels of the CD62L homing
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stimulatory receptor/ligand interactions, including CD33-related
Siglecs (Nguyen et al., 2006), ICAMs (Walter et al., 2005) that could
differentially modulate CD4+ lymphocyte activation and prolifera-
tion in vitro and in vivo. The basis of these differences between these
two species, as well as their relevance to in vivo functional differences,
will require further exploration.
In summary, we report here a new activation protocol that renders
chimpanzee CD4 T-cells capable of replicating R5 tropic HIV-1 strains.
This activation protocol has already proven useful to assess the
biological relevance of an HIV-1 matrix protein adaptive change
selected upon cross-species transmission of SIVcpz to humans and to
analyze the replication potential of novel fecal-consensus SIVcpz and
SIVgor molecular clones in chimpanzee CD4+ lymphocytes (Takehisa
et al., 2009; Takehisa et al., 2007; Wain et al., 2007). However,
unanswered questions remain. We show here that chimpanzee
donors vary signiﬁcantly in the level of HIV-1 replication, much
more so than human donors. The receptor and coreceptor expression
levels are equivalent between human and chimpanzees (Fig. 4); thus,
it seems improbable that, like natural SIV hosts such as sooty
mangabeys and African greenmonkeys (Beaumier et al., 2009; Sodora
et al., 2009), CD4 or CCR5 expression differences account for the
susceptibility differences. Moreover, we have recently identiﬁed
additional HIV-1 strains and primary isolates that, similar to JRSCF,
do not replicate in chimpanzee lymphocytes, including strains that
use CXCR4 as coreceptor. These results point to chimpanzee-speciﬁc
host factors can may block or modulate HIV-1 replication in
chimpanzee lymphocytes. These restriction factors are likely different
from currently know human HIV-1 restriction factors such as TRIM5a,
APOBEC3G, since the human and chimpanzee alleles seem equivalent
with respect to their anti-HIV-1 function (Kratovac et al., 2008;
Sawyer et al., 2004; Song et al., 2005a). Our new lymphocyte
activation approach provides the basis for comparative studies of
human and chimpanzee susceptibility to HIV-1 that could lead to the
identiﬁcation of novel host factors that control or are required for HIV-
1 replication.Materials and methods
Chimpanzee and human blood
Blood samples were collected from captive chimpanzees housed at
the Yerkes Primate Research Center during their annual health survey,
a procedure approved by the Emory Institutional Animal Care and Use
Committee. None of the chimpanzees studied were infected with HIV-
1 or SIVcpz. Human blood from healthy HIV-1-negative individuals
was obtained from Research Blood Components (Boston, MA). Blood
samples, collected using ACD as anticoagulant, were processed within
24 h.Isolation of CD4+ cells
Chimpanzee and human peripheral blood mononuclear cells
(PBMCs) were isolated by density separation using Ficoll-Hypaque
Plus (GE-Healthcare, Piscataway, NJ) and centrifuged at 1800 rpm for
25 min at 22 °C. Interphase mononuclear cells were washed once at
room temperature in Hanks balanced saline solution (HBSS)+4 mM
EDTA and once at 4 °C in HBSS+1% FCS. CD4+ cells were puriﬁed
from total PBMCs by positive selection using magnetic MicroBeads
and an autoMACS™ (Miltenyi Biotec, Auburn, CA). Human CD4
MicroBeads were used for human and non-human primate CD4
MicroBeads for chimpanzee, according to manufacturer's protocols
and recommendations. Purity of the CD4+ population was deter-
mined to be N90% by ﬂow cytometric analysis.Standard CD4+ T lymphocyte activation
Five to ten million CD4+ mononuclear cells (monocytes and
lymphocytes) in 3 ml of RPMI media+15% FCS were placed in one
well of a 6-well plate in the presence of PHA (PHA-P; Sigma-Aldridge,
St. Louis, MO) (3 μg/ml) or Staphylococcal enterotoxin B (SEB; Sigma-
Aldridge) (3 μg/ml) for 48 to 72 h at 37 °C in a 5% CO2 incubator.
Following activation, cells were cultured at 1×106 /ml and infected in
complete media (RPMI+10% FBS with 30 U/ml of IL-2; Roche
Diagnostics).Improved CD4+ T lymphocyte activation
Brieﬂy, the optimized activation procedure can be divided in three
steps: (i) to enable efﬁcient lymphocyte activation and proliferation,
the ratio of monocytes to lymphocytes in the CD4+ positively
selected cell fraction is changed from 1:10 to about 1:2 by successive
plating; (ii) monocytes are pulsed overnight with SEB; and (iii) upon
monocyte differentiation in macrophages, CD4+ lymphocytes are
allowed to proliferate for 6 to 7 days. For the ﬁrst step, 20 to 40million
CD4+ mononuclear cells (monocytes and lymphocytes) were plated
in 2 ml of serum-free RPMI media in one well of a 6-well plate for
30 min at 37 °C in a 5% CO2 incubator. Cells were allowed to adhere,
and non-adherent cells were subsequently placed into a new well.
This procedurewas repeated a total of three times to increase the ratio
of adherent monocyte/macrophages (10–25% of the initial cells) to
non-adherent CD4+ T lymphocytes (Koller et al., 1973). For the
second step, monocytes and lymphocytes were pulsed for 12–15 h
with 3 μg/ml of SEB in 1.5 ml RPMI+15% FCS. For the third step, SEB
was removed by media exchange and washing non-adherent cells
with HBSS, monocytes were differentiated in 2.5 ml of DMEM with
10% giant cell tumor conditioned medium (BioVeris Corp., Gaithers-
burg, MD) and 10% Human AB serum (Fisher Bioreagents, Fair Lawn,
NJ); lymphocytes were then allowed to proliferate for 6–7 days.
During this time, an additional 2 ml of the same media was added to
each well to sustain lymphocyte proliferation. Combining non-
adherent cells from all wells, 30–40 million activated CD4+
lymphocytes were typically harvested by days 6–7. Following
proliferation, cells were cultured at a density of 1×106/ml in
complete media (DMEM+10% FBS with 30 U/ml of IL-2; Roche
Diagnostics) for 24 h prior to infection. Culturing the cells in complete
media for at least 24 h prior to infection increased the activated cells
susceptibility to HIV-1 infection (data not shown). Once activated,
CD4+ lymphocytes continued to proliferate in complete media in the
absence of further stimuli for at least 2 weeks.Immunoﬂuorescent staining and ﬂow cytometric analysis
Activated T-cells were transferred in staining buffer (PBS+2%
FBS+0.2% sodium azide), and the following conjugated monoclonal
antibodies against human differentiation antigens were used to
determine the cell surface expression of the corresponding markers
(clone number indicated in parenthesis): anti-CD3 (UCHT1), anti-
CD8 (RPA-T8), anti-CD4 (RPA-T4), anti-CD69 (FN50), anti-HLA-DR
(G46-6), anti-CD25 (M-A251), anti-CD45RO (UCHL1), anti-CD45RA
(HI100), anti-CD62L (Dreg 56), anti-CD184 (12G5), all from BD
Biosciences (San Jose, CA) and anti-CD195 (CTC5) from R&D Systems
Inc. (Minneapolis, MN). Stained cells were analyzed on a Cell Lab
Quanta™ SC MPL ﬂow cytometer (Beckman Coulter, Fullerton, CA)
and a minimum of 10,000 events per three-color stain were collected.
Matching antibody isotype control stains were included as negative
controls for each antibody combination in all runs. Results were
analyzed using Cell Lab Quanta™ software (Beckman Coulter) and
CellQuest™ Pro (BD Biosciences).
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HIV-1 SG3, YU2, JRCSF and ADA virus stocks were generated by
transfecting the respective full-length molecular clone into 293T cells
using FuGene 6 (Roche Applied Science, Indianapolis, IN) according to
manufacturer's protocol. Forty-eight to seventy-two hours post-
transfection, culture supernatants were harvested, clariﬁed by low
speed centrifugation, and aliquots were stored at −70 °C. The HIV-1
Bal isolate was obtained from the NIH AIDS Research and Reference
Reagent Program and propagated on SEB-activated human CD4+
lymphocytes to generate virus stock. Culture supernatants were
harvested, clariﬁed by low speed centrifugation, and aliquots were
stored at −70 °C. Infectious titers of virus stocks were determined
using the JC53BL assay as described previously (Derdeyn et al., 2000;
Wei et al., 2002).
Infection and replication kinetics
Chimpanzee- and human-activated CD4+ T lymphocytes (0.5
106/vial) were infected overnight at a multiplicity of infection (MOI)
of 0.1 (based on JC53BL infectious titer) in 300 μl of complete media.
Overnight incubation in this small volume was necessary for optimal
infection of chimpanzee lymphocytes. After 12–15 h, cells were
washed three times with HBSS medium and plated in a well of a 24-
well plate in 2 ml of complete media. Forty microliters of supernatant
was collected every 2–3 days and stored at−70 °C. To monitor virus
replication, the p24 viral antigen was quantiﬁed in the culture
supernatants using the HIV-1 p24 antigen EIA kit according to the
manufacturer's protocol (Beckman Coulter).
Bio-Plex™ cytokine assay
Activated lymphocytes culture supernatants were collected after
24 h incubation in complete media and stored at −70 °C. Cytokines
concentration for IL-4, IFN-γ, CCL3 and CCL5 were determined from
50 μl of supernatant using the corresponding Bio-Plex™ Human
Cytokine Assay according to manufacturer's protocol (Bio-Rad
Laboratories, Hercules, CA). Data were collected using a Bio-Plex™
200 suspension array system (Bio-Rad Laboratories), and statistical
analyses of the results were performed using Prism software version
4.0c for Macintosh (GraphPad Software Inc.).
Statistical analyses
The nonparametric Mann–Whitney U test (two-tailed) was used
to analyze the cell surface markers expression and cytokine
production differences between chimpanzee and human donors.
Differences in expression between the two groups were considered
signiﬁcant when p values were ≤0.01. Correlation analysis for the
HIV-1 SG3 and YU2 replication in activated chimpanzee T-cells was
performed using the Spearman's rank correlation test. These statis-
tical analyses were performed using Prism software version 4.0c for
Macintosh (GraphPad Software Inc.).
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